Apexxnar suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (20-valent

DRUG3 trials

Sponsors

Leiden University Medical Center, GlaxoSmithKline Biologicals, Pfizer Inc.

Conditions

Healthy volunteersRSV-associated (subtypes A and B) disease in adults aged 60 years of age and older.VACCINE-TYPE RADIOLOGICALLY-CONFIRMED COMMUNITY-ACQUIRED PNEUMONIA

Phase 2

Optimisation of lymph node fine needle aspiration to study pneumococcal vaccine-induced immunity

RecruitingCTIS2022-501519-15-00

Leiden University Medical CenterHealthy volunteers

Start: 2023-04-01Target: 5Updated: 2024-06-20

Phase 3

A Phase III, open-label, randomized, controlled, multi-country study to evaluate the immune response, safety and reactogenicity of RSVPreF3 OA investigational vaccine when co-administered with 20-valent pneumococcal conjugate vaccine (PCV20) in adults aged 60 years and older.

CompletedCTIS2022-501988-40-00

GlaxoSmithKline BiologicalsRSV-associated (subtypes A and B) disease in adults aged 60 years of age and older.

Start: 2023-08-17End: 2024-05-07Target: 407Updated: 2024-03-25

Phase 4

B7471015 - A PHASE 4 STUDY USING A TEST-NEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE AGAINST VACCINE-TYPE RADIOLOGICALLY-CONFIRMED COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS ≥65 YEARS OF AGE

RecruitingCTIS2023-507293-40-00

Pfizer Inc.VACCINE-TYPE RADIOLOGICALLY-CONFIRMED COMMUNITY-ACQUIRED PNEUMONIA

Start: 2024-04-11Target: 2500Updated: 2025-02-19